Susceptibility of Streptococcus pneumoniae to Fluoroquinolones in Canada

Ciprofloxacin, the first fluoroquinolone to be used to treat lower respiratory tract infections (LRTI), demonstrates poor potency against Streptococcus pneumoniae, and its use has been associated with the emergence of resistance. During the last decade, fluoroquinolones with enhanced in vitro activi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Patel, Samir N., McGeer, Allison, Melano, Roberto, Tyrrell, Gregory J., Green, Karen, Pillai, Dylan R., Low, Donald E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2011
Soggetti:
Epidemiology and Surveillance
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147653/
https://ncbi.nlm.nih.gov/pubmed/21628545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00237-11
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi